Malignant gliomas are highly heterogeneous brain tumors in molecular genetic background. Despite the many recent advances in the understanding of this disease, patients with adult high-grade gliomas retain a notoriously poor prognosis. Fusions involving oncogenes have been reported in gliomas and may serve as novel therapeutic targets to date. Understanding the gene fusions and how they regulate oncogenesis and malignant progression will contribute to explore new approaches for personalized treatment. By now, studies on gene fusions in gliomas remain limited. However, some current clinical trials targeting fusion genes have presented exciting preliminary findings. The aim of this review is to summarize all the reported fusion genes in high-grade gliomas so far, discuss the characterization of some of the most popular gene fusions occurring in malignant gliomas, as well as their function in tumorigenesis, and the underlying clinical implication as therapeutic targets.
|Original language||English (US)|
|Journal||Frontiers in Neurology|
|State||Published - Oct 4 2021|
Bibliographical noteFunding Information:
This work was supported by the National Natural Science Foundation of China (No. 81871013), Beijing Municipal Education Commission Science and Technology Plan General Project (No. 1192050172), and Beijing Tiantan Hospital Young Scientist Program (YSP201705).
© Copyright © 2021 You, Fan, Hu, Jiang and Chen.
- fusion gene
- high-grade glioma
- personalized cancer medicine
- targeted therapy